Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks
Theranostics · 2023 · 13 (2) · 704-723
DOI: 10.7150/thno.80184 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Theranostics, 2023. Verfasst von Ke Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Kelch-Like ECH-Associated Protein 1, Lung Neoplasms, NF-E2-Related Factor 2. Die Arbeit wurde bisher 63-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The Kelch-like ECH-associated protein 1/nuclear factor erythroid-derived 2-like 2 (KEAP1/NRF2) pathway is well recognized as a key regulator of redox homeostasis, protecting cells from oxidative stress and xenobiotics under physiological circumstances. Cancer cells often hijack this pathway during initiation and progression, with aberrant KEAP1-NRF2 activity predominantly observed in non-small cell lung cancer (NSCLC), suggesting that cell/tissue-of-origin is likely to influence the genetic selection during malignant transformation. Hyperactivation of NRF2 confers a multi-faceted role, and recently, increasing evidence shows that a close interplay between metabolic reprogramming and tumor immunity remodelling contributes to its aggressiveness, treatment resistance (radio-/chemo-/immune-therapy) and susceptibility to metastases. Here, we discuss in detail the special metabolic and immune fitness enabled by KEAP1-NRF2 aberration in NSCLC. Furthermore, we summarize the similarities and differences in the dysregulated KEAP1-NRF2 pathway between two major histo-subtypes of NSCLC, provide mechanistic insights on the poor response to immunotherapy despite their high immunogenicity, and outline evolving strategies to treat this recalcitrant cancer subset. Finally, we integrate bioinformatic analysis of publicly available datasets to illustrate the new partners/effectors in NRF2-addicted cancer cells, which may provide new insights into context-directed treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, People's Republic of China.
- Department of Thoracic Surgery, Anhui Chest Hospital, Hefei, 230000, China.
- Wyss Institute for Biologically Inspired Engineering, Harvard University; Boston, MA 02115, USA.
- Division of General Thoracic Surgery, Department of BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern; Bern, 3010, Switzerland.
Zitieren
APA
Xu, K., Ma, J., Hall, S. R. R., Peng, R. W., Yang, H., & Yao, F. (2023). Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks. Theranostics, 13(2), 704-723. https://doi.org/10.7150/thno.80184
Vancouver
Xu K, Ma J, Hall SRR, Peng RW, Yang H, Yao F. Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks. Theranostics. 2023;13(2):704-723. doi:10.7150/thno.80184
BibTeX
@article{Xu2023,
author = {Xu, Ke and Ma, Jie and Hall, Sean R R and Peng, Ren-Wang and Yang, Haitang and Yao, Feng},
title = {Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks},
journal = {Theranostics},
year = {2023},
volume = {13},
number = {2},
pages = {704--723},
doi = {10.7150/thno.80184}
}
EUVIMED